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Abstract
Background: Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours
like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were
compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer.
Methods: A multi-national, open-label, controlled, randomized, parallel-group, phase II pilot study was conducted in 20
centers in 7 countries. Cilengitide was administered at 600 mg/m2 twice weekly for 4 weeks per cycle and gemcitabine
at 1000 mg/m2 for 3 weeks followed by a week of rest per cycle. The planned treatment period was 6 four-week cycles.
The primary endpoint of the study was overall survival and the secondary endpoints were progression-free survival (PFS),
response rate, quality of life (QoL), effects on biological markers of disease (CA 19.9) and angiogenesis (vascular
endothelial growth factor and basic fibroblast growth factor), and safety. An ancillary study investigated the
pharmacokinetics of both drugs in a subset of patients.
Results:  Eighty-nine patients were randomized. The median overall survival was 6.7 months for Cilengitide and
gemcitabine and 7.7 months for gemcitabine alone. The median PFS times were 3.6 months and 3.8 months, respectively.
The overall response rates were 17% and 14%, and the tumor growth control rates were 54% and 56%, respectively.
Changes in the levels of CA 19.9 went in line with the clinical course of the disease, but no apparent relationships were
seen with the biological markers of angiogenesis. QoL and safety evaluations were comparable between treatment
groups. Pharmacokinetic studies showed no influence of gemcitabine on the pharmacokinetic parameters of Cilengitide
and vice versa.
Conclusion: There were no clinically important differences observed regarding efficacy, safety and QoL between the
groups. The observations lay in the range of other clinical studies in this setting. The combination regimen was well
tolerated with no adverse effects on the safety, tolerability and pharmacokinetics of either agent.
Background
Cilengitide (EMD 121974, Cyclo-l-Arg-l-Asp-d-Phe-N
(Me) l-Val) is a new low-molecular weight anti-angiogen-
esis agent. It is a cyclic peptide inhibitor of the endothelial
cell surface receptors, integrins ανβ 3 and ανβ 5 [1].
Integrins are responsible for cell adhesion to the extracel-
lular matrix. They bind to a number of extracellular matrix
components including fibronectin, laminin, collagen, vit-
ronectin, fibrinogen and thrombospondin. These mole-
cules form the vascular matrix and subendothelial
basement membrane of blood vessels [2]. The endothelial
expression of the extracellular matrix molecules changes
during angiogenesis under the regulation of integrins. The
key role integrins play in tumor angiogenesis is illustrated
by studies showing their involvement in cell migration,
proliferation and survival [3]. The integrin ανβ 3, which
binds to a number of extracellular matrix proteins, is not
generally expressed in normal tissues but is significantly
upregulated on blood vessels undergoing angiogenesis
[4]. The distinct but functionally related ανβ 5 receptor
differs from ανβ 3 in a way that ανβ 3 plays a critical role
in basic fibroblast growth factor (bFGF)-stimulated angio-
genesis and ανβ 5 in vascular endothelial growth factor
(VEGF)-induced angiogenesis [5]. Both ανβ 3 and ανβ 5
are expressed on tumor cells [6-9], and in some cancers
expression has been linked with a poor prognosis [10].
Cilengitide inhibits the binding of vitronectin to ανβ 3
with a 50% inhibitory concentration (IC50) of 1 nM and
to ανβ 5 with an IC50 of 140 nM [11]. Cilengitide inhibits
tumor-mediated angiogenesis and the growth of human
xenografted tumors [12,13]. Non-growth-inhibitory
doses of Cilengitide were shown to increase the efficacy of
radioimmunotherapy in a breast cancer xenograft model
[14]. In vitro studies have shown that Cilengitide not only
inhibits angiogenesis but also is directly toxic to ανβ 3-
and ανβ 5-expressing tumor cell lines [15]. Phase I data
showed that, in patients with advanced solid tumors,
Cilengitide (30 mg/m2  to 1600 mg/m2) given twice
weekly was well tolerated and resulted in prolonged stable
disease in 3 patients [16].
Carcinoma of the pancreas is an aggressive human cancer
noted for its early metastatic potential and poor prognosis
[17]. The disease accounts for around 32,000 deaths a
year in the United States [18], and around 47.000 in West-
ern Europe [19]. The median survival time for patients
with locally advanced disease is 6 to 10 months and for
those with metastases the median survival time is only 3
to 6 months. Most patients present with advanced disease
and the symptoms of the disease cause substantial mor-
bidity. It has been suggested that, in addition to the tradi-
tional goals of clinical trials (response rate, survival),
subjective measures such as disease stabilization and
symptom palliation are particularly important for
patients with pancreatic cancer [20]. In recent years gem-
citabine has replaced 5-fluorouracil-based chemotherapy
as the preferred choice for first line palliative chemother-
apy in patients with advanced pancreatic cancer. Although
it has shown clinical benefit, the median survival time ofBMC Cancer 2006, 6:285 http://www.biomedcentral.com/1471-2407/6/285
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patients treated with gemcitabine alone is 5.7 months
[21] and with gemcitabine in combination with 5-fluoru-
racil 6.7 months [22]. There is a clear need for effective
new agents or adjuncts to existing therapies for patients
with cancer of the pancreas.
Pancreatic carcinoma like other tumors also depends on
the development of an adequate blood supply through
angiogenesis. The pivotal role of angiogenesis in primary
tumor growth and metastasis has been recognized many
years before. Inhibition of neo-angiogenesis is a new and
attractive target for tumor therapy, since it theoretically
offers the hope of long-term control of tumor progression.
Antiangiogenic therapy offers a number of potential ben-
efits including lack of resistance to some agents, synergis-
tic interaction to other modalities and potentially reduced
toxicity compared with conventional agents. Administra-
tion of angiogenesis inhibitors might keep the tumor and
its metastases stable in growth and let co-administration
of cytotoxic drugs kill it. The anti-neoplastic actions of
angiogenic inhibitors and cytotoxic agents are clearly dif-
ferent. Treatment with antiangiogenic agents could inter-
act in a positive way with a variety of anti-cancer therapies,
and the anti-metastatic and anti-tumor effects of combi-
nation therapy were stronger than those of angiogenic
inhibitors alone and cytotoxic agents alone.
Towards this goal, the present study was designed to com-
pare the effects of treatment with Cilengitide and gemcit-
abine with gemcitabine alone. The primary objective of
the study was to investigate overall survival in patients
with advanced unresectable pancreatic cancer. The sec-
ondary objectives were to determine the effects of these
therapies on progression-free survival (PFS), response
rates, tumor growth control, the biological responses of
surrogate tumor markers and angiogenic growth factors,
safety and tolerability, and quality of life (QoL). An ancil-
lary study investigated the pharmacokinetics of Cilen-
gitide and gemcitabine in a subset of patients.
Methods
Patients
Patients with advanced unresectable pancreatic cancer
were enrolled. Eligibility criteria included age ≥ 18 years,
diagnosed (histologically or cytologically) with or with-
out metastases, at least one bidimensionally measurable
lesion, a Karnofsky performance score of ≥ 70%, a life
expectancy of at least 12 weeks, and written informed con-
sent. The main exclusion criteria were prior chemotherapy
and/or major surgery related to pancreatic cancer before
study entry with the exception of palliative surgery, brain
metastases, a pancreatic tumor of neuroendocrine origin,
second primary malignancies, inadequate liver and renal
functions, inadequate bone marrow reserve, a history of
cerebrovascular accident or repeated transient ischemic
attacks and cardiac or cardiovascular abnormality. The
study was approved by the independent Ethics Commit-
tees and by the Local Authorities of the different institu-
tions according to country specific laws before the start of
the study.
Study design and treatment
This was a multi-national, open-label, controlled, rand-
omized, parallel-group, phase II pilot study, conducted in
20 centers in 7 countries (Austria, Belgium, France, Ger-
many, Spain, Switzerland, and the United Kingdom). Eli-
gible patients were randomized to receive either
Cilengitide and gemcitabine or gemcitabine alone. The
Pocock minimization method [23] was applied for rand-
omization using factors for center and for locally
advanced or metastatic disease following the definition
according to the tumor-node-metastasis (TNM) classifica-
tion and histopathological grading system of the Interna-
tional Union Against Cancer. Cilengitide (600 mg/m2)
was administered twice weekly as a 1 hour intravenous
(IV) infusion for 4 consecutive weeks (1 cycle). Gemcitab-
ine (1000 mg/m2) was administered as a weekly 30-
minute IV infusion once weekly for 3 weeks followed by 1
week of rest (1 cycle). In the drug combination group, on
the days on which both drugs were given, Cilengitide was
given immediately prior to gemcitabine. The planned
treatment period was 24 weeks (6 cycles), but patients
responding to either regimen could continue treatment
up to a maximum of 48 weeks. Patients experiencing
dose-limiting toxicities, as assessed by the National Can-
cer Institute Common Toxicity Criteria (NCI-CTC) grad-
ing criteria, had their treatment reduced, delayed or
discontinued. Any change was based on patient hemato-
logical and/or non-hematological parameters on the
intended day of treatment as well as the maximum drug-
induced toxicity grade observed between dosing.
Survival and tumor response evaluations
Overall survival was defined as the time from the start of
study drug administration to death. PFS was defined as
the time interval between the date of randomization and
the date of disease progression or death whichever came
first. If neither was observed the patient was censored at
the date of the last follow-up examination. A computed
tomography or magnetic resonance imaging scan of target
lesions was performed at baseline, weeks 9 and 17, and at
the end of treatment to assess tumor size and treatment
response. Unscheduled scans were conducted to confirm
disease progression. Tumor response was assessed accord-
ing to the amended World Health Organization (WHO)
criteria for response based on the size of target lesions.
Quality of Life evaluations
Quality of life (QoL) was assessed using the European
Organization for Research and Treatment of CancerBMC Cancer 2006, 6:285 http://www.biomedcentral.com/1471-2407/6/285
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(EORTC) QoL core questionnaire (QLQ-C30, Version
3.0) in conjunction with the EORTC Pancreatic Module
(EORTC QLQ-PAN26). QLQ-C30 is a self-administered
30-item questionnaire and incorporates 5 functional
scales, 3 symptom scales and a global health/QoL scale.
EORTC-PAN26 is a 26-item questionnaire addressing
pancreas cancer specific symptoms and the side effects
from conventional therapy. Assessments were made at
weeks 1, 9, 17, 25 and at the end of treatment. QoL data
were analyzed descriptively due to the small number of
patients enrolled in the study. The descriptive data were
interpreted as suggested by Osaba et al. [24] with a mean
change of 10 to 20 representing a "moderate" change and
a change of greater than 20 representing a "large" change
in QoL.
Biological response
Biological response was assessed by measuring the levels
of tumor markers associated with pancreatic cancer (CA
19-9) or angiogenesis (VEGF, bFGF). Measurements by
means of commercially available ELISA kits were made of
CA 19-9 in serum, VEGF in plasma and serum and bFGF
in plasma, serum and urine at weeks 1, 5, 9, 13, 17, 21 and
at the final visit.
Safety
The before treatment and 4-weekly evaluations included a
physical examination and laboratory investigations
(blood counts, biochemical profile, urinalysis). Assess-
ments were also made of Karnofsky performance status
and vital signs. Before the start of the study, at the end of
the study and when clinically indicated during the study
chest X-rays and 12-lead electrocardiograms were per-
formed. Adverse events were monitored and evaluated for
frequency, duration, severity (mild, moderate, severe, life-
threatening) and possible relationship to study medica-
tion. Toxicity was assessed according to NCI-CTC Version
2. All adverse events whether reported by a patient or
observed by an investigator or study nurse were docu-
mented, regardless of whether they were considered to be
drug-related, together with any medical intervention.
Pharmacokinetic analysis
An ancillary pharmacokinetic study was carried out using
previously described methodology [25,26] in a subset of
patients receiving either Cilengitide and gemcitabine or
gemcitabine alone. Blood samples were taken following
drug administration and the plasma extracted immedi-
ately and stored. Blood samples for determination of
Cilengitide were collected at the following time points:
day 1 immediately before Cilengitide infusion and after 1
h (end of infusion); day 8 immediately before Cilengitide
infusion and after 1 h (end of infusion) and 0.5 h, 1 h, 2
h, 3 h, 4 h, 7 h, and 11 h after end of Cilengitide infusion.
Blood samples for gemcitabine analysis were collected in
both treatment arms on day 1 and day 8 at the following
time points: 0 h (immediately before start of infusion of
gemcitabine), 0.5 h (at the end of infusion of gemcitab-
ine) and 0.5 h, 1.5 h, 2.5 h, and 3.5 h after end of gemcit-
abine infusion.
Analysis was carried out at a single laboratory using high-
performance liquid chromatography-tandem mass spec-
trometry. Calculation of pharmacokinetic parameters was
performed according to non-compartmental standard
methods. Pharmacokinetic analyses included maximum
plasma concentration (Cmax), time to maximum concen-
tration (tmax), area under the curve from time zero to the
last sampling time (AUC0-t), area under the curve from
time zero to infinity (AUC0-∝), apparent elimination rate
constant (λz), apparent terminal elimination half-life
associated with the negative terminal slope (t1/2), total
body clearance of drug from plasma (CL) and the volume
of distribution at steady state (Vss). The lower limits of
quantification for Cilengitide and gemcitabine in plasma
were 1 ng/mL and 50 ng/mL, respectively. For the plasma
quality control samples of Cilengitide the interbatch coef-
ficient of variation (CV) was 3.4% to 9.2% and the inter-
batch accuracy was 97% to 104%. For the plasma quality
control samples of gemcitabine, the interbatch CV was
5.6% to 9.4% and the interbatch accuracy was 93.5% to
104%.
Statistical analysis
The sample size of the trial was determined by clinical fea-
sibility. No inferential statistical comparison of the two
treatment arms was planned. The aim was to obtain infor-
mation on safety and feasibility as well as trends in effi-
cacy by determination of overall survival as primary and
progression-free survival (PFS), response rate, quality of
life (QoL), effects on biological markers of disease (CA
19.9) and angiogenesis (vascular endothelial growth fac-
tor and basic fibroblast growth factor) and safety as sec-
ondary endpoints. Confidence intervals were presented at
the 95%-confidence level. The data of this phase II pilot-
and feasibility study, are presented in a descriptive man-
ner. The primary analysis of survival (time to death from
any cause) was conducted using the intention-to-treat
(ITT) population. An additional supportive analysis using
the Per Protocol (PP) population was conducted. The sec-
ondary objectives were to determine PFS, response rates,
safety and tolerability, QoL, biological response, and
pharmacokinetics. Time to death or progression was ana-
lyzed using PROC LIFETEST.
Results
Patient characteristics
Eighty-nine patients were enrolled, randomized and
included in the ITT population. Three patients died before
receipt of the study drug making 86 patients evaluable forBMC Cancer 2006, 6:285 http://www.biomedcentral.com/1471-2407/6/285
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safety. Seventy-six patients were included in the PP popu-
lation. Of the 13 major protocol violations, 12 received
less than 4 weeks of treatment and one met an exclusion
criterion. The demographic and clinical characteristics of
the ITT population were similar for each treatment group
(Table 1). All tumors were advanced and unresectable and
all were histologically confirmed, with the exception of
one patient in the Cilengitide and gemcitabine group.
Three patients received other prior tumor-related thera-
pies, and one patient in the gemcitabine only group
received prior palliative radiotherapy. One patient in the
Cilengitide and gemcitabine had a partial resection. The
aforementioned 4 patients were granted waivers, because
of protocol violations classified as minor and they were
included in the PP population.
Efficacy
Overall survival for each treatment group is presented in
table 2 and figure 1 (progression free survival is shown in
figure 2). There were no differences observed in survival
between the ITT and PP populations. Although the initial
treatment period was 6 months, patients responding to
therapy could continue treatment for a further 6 months.
At the time of the database closure, two patients with sta-
ble disease continued with the combination regimen on
their own request because they had at least a subjective
benefit from treatment. Response rate data are given in
Table 3. There was no difference observed in tumor
response between the ITT and PP populations.
Biological response
The intra-individual course of CA 19-9 concentrations was
observed to correlate with the clinical course, particularly
in responders. The baseline levels were not well balanced
in the treatment groups. (the median CA 19-9 concentra-
tion was greater in the gemcitabine group (1205.5 U/mL)
than in the EMD 121974 and gemcitabine group (726.5
U/mL)). At week 5, CA 19-9 concentrations had declined
in both groups and stayed relatively stable thereafter,
remaining below the baseline concentration in both treat-
ment groups at all subsequent time points.
No apparent relationship with plasma or serum VEGF,
plasma or serum bFGF, or urinary bFGF concentrations
was observed in either treatment groups, and there was no
consistent pattern of change in any angiogenic growth fac-
tor level with time. The intra-individual course of these
parameters was not observed to correlate with the clinical
course. There were no apparent differences in the tumor
marker data between the treatment groups at any time
point. The results for the ITT and PP populations were
broadly similar, except at week 17 in the PP population
urinary bFGF was higher in the Cilengitide and gemcitab-
ine group than in the gemcitabine alone group.
Quality of Life
The number of patients receiving treatment at each time
point decreased with time from 44 to 35 to 26 at weeks 1,
9 and 17 in the Cilengitide and gemcitabine group and
from 42 to 30 to 20 in the gemcitabine alone group,
respectively. At later time points the number of patients
contributing to the QoL analysis was too small for any
reliable conclusions to be made. A "moderate" difference
was observed at week 9 for the pain scale in favor of gem-
citabine alone whereas a "moderate" difference in favor of
the combination treatment was seen in the insomnia
scales at week 9 and in the diarrhea scale at week 17. The
change from baseline was examined for the 15 subscales
of the QLC-C30. In the Cilengitide and gemcitabine
group, 61% and 56% of patients reported an improved
global health status at weeks 9 and 17 compared with
50% and 47% in the gemcitabine alone treatment group.
Patients who remained on the study for a longer period of
time appeared to have a better QoL at baseline. The QLQ-
PAN26 scale showed a "moderate" difference in favor of
the gemcitabine alone group at week 9 for the flatulence
Table 1: Patient Characteristics
Cilengitide + Gemcitabine n = 46 Gemcitabine n = 43 Total n = 89
Age, years Median 68 66 67
Range 40–80 56–80 40–80
Gender (n, %) Male 26 (57%) 18 (42%) 44 (49%)
Female 20 (43%) 25 (58%) 45 (51%)
Stage III 3 (7%) 4 (9%) 7 (8%)
IV 3 (7%) 1 (2%) 4 (4%)
IVa 3 (7%) 4 (9%) 7 (8%)
IVb 37 (80%) 34 (79%) 71 (80%)
KP score at screening 70 3 (7%) 2 (5%) 5 (6%)
80 19 (41%) 18 (42%) 37 (42%)
90 18 (39%) 17 (40%) 35 (40%)
100 6 (13%) 6 (14%) 12 (13%)
Abbreviation: KP, Karnofsky performance.BMC Cancer 2006, 6:285 http://www.biomedcentral.com/1471-2407/6/285
Page 6 of 12
(page number not for citation purposes)
scale, and at week 17 for the body image, weight, future
health and planning activities scales. "Moderate" differ-
ences in favor of the combination treatment were
observed at week 17 for altered bowel habit, health care
satisfaction and sexuality scales.
Drug exposure
Table 4 summarizes the drug exposure data. The mean
number of completed cycles and the mean duration of
treatment were slightly greater in the Cilengitide and gem-
citabine treatment group (4.8 cycles and 134 days) than in
the gemcitabine alone group (4.1 cycles and 120 days).
The relative dose intensity (RDI) for both treatment
groups was very close to the planned dose intensity and
similar in both treatment groups.
Safety
An overview of the adverse events is given in Table 5. All
86 patients experienced at least one adverse event during
the treatment period of the study. The number of events
was greater in the combination group than in the gemcit-
abine alone group. The most frequently reported adverse
events that occurred during the treatment period were
nausea (57% of patients), fatigue (49%), anemia (45%),
vomiting (43%), abdominal pain (38%), dyspepsia
(35%), thrombocytopenia (34%), and leukopenia (33%).
Nausea (64% vs 50%), dyspepsia (41% vs 29%), dyspnea
(27% vs 14%), shivering (21% vs 7%) and fever (34% vs
24%) were more frequent in the Cilengitide and gemcit-
abine group than the gemcitabine alone group, but taken
solely the treatment-related events, only shivering
remains more frequent (14% vs. 2%). Gamma-glutamyl
transferase elevations (29% vs 16%), ascites (26% vs 9%),
cholestasis (26% vs 7%), urinary tract infection (21% vs
5%) and jaundice (19% vs 2%) were reported more fre-
quently in the gemcitabine alone group than in the Cilen-
gitide and gemcitabine group. The incidence of other
adverse events was observed to be similar in the treatment
groups. A total number of 346 and 278 possibly related
adverse events occurred in 84% (37) and 76% (32) of the
patients in the Cilengitide and gemcitabine group and the
gemcitabine alone group, respectively. The most fre-
quently reported adverse events that were considered pos-
sibly related to the study medications were nausea,
leukopenia, thrombocytopenia, and anemia (Table 6). All
were of a comparable frequency in both groups, with the
exception of leukopenia (36% vs 26%), which was
reported by slightly more patients in the Cilengitide and
gemcitabine group. In Cilengitide and gemcitabine group
a number of 12 and in the gemcitabine alone group in
total 8 possibly related serious adverse events were
reported, respectively (Table 7).
The analysis of vital signs, physical examination, weight
changes, chest X-rays, and ECGs did not raise any unex-
pected issues of clinical importance.
Pharmacokinetic data
Eighteen patients were included in the pharmacokinetic
sub-study (12 in the Cilengitide and gemcitabine group;
and 6 in the gemcitabine alone group, data not shown).
For Cilengitide non-compartmental pharmacokinetic
analysis was performed on 11 data sets, 10 in week 2 and
1 in week 3. AUCextra provided more than 25% of AUC0-∝
for one patient, and so the value and derived parameters
(AUC0-∝, λz, CL, Vss) were flagged as unreliable and not
included in the statistical analysis. Maximum plasma con-
centrations of Cilengitide were, in general, reached at 1 h
post-dose (i.e. at the end of infusion). In most profiles, a
distribution phase could be identified upon visual inspec-
tion. Thereafter, concentrations declined with a t1/2 of
about 3 h and were thus measurable over the sampling
period up to 12 h after start of infusion. There was no
apparent difference between mean concentrations meas-
ured at the end of infusion in Week 1 (75410 ± 31530 ng/
Progression free survival time for the ITT population of  patients randomized to receive (red) Cilengitide (600 mg/m2)  and gemcitabine (1000 mg/m2) or (blue) gemcitabine alone  (1000 mg/m2) Figure 2
Progression free survival time for the ITT population of 
patients randomized to receive (red) Cilengitide (600 mg/m2) 
and gemcitabine (1000 mg/m2) or (blue) gemcitabine alone 
(1000 mg/m2).
Time to death for the ITT population of patients randomized  to receive (red) Cilengitide (600 mg/m2) and gemcitabine  (1000 mg/m2) or (blue) gemcitabine alone (1000 mg/m2) Figure 1
Time to death for the ITT population of patients randomized 
to receive (red) Cilengitide (600 mg/m2) and gemcitabine 
(1000 mg/m2) or (blue) gemcitabine alone (1000 mg/m2).BMC Cancer 2006, 6:285 http://www.biomedcentral.com/1471-2407/6/285
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mL) in comparison to those in Week 2 (62182 ± 12345
ng/mL). The pharmacokinetic parameters of Cilengitide
are summarized in Table 8.
For gemcitabine, maximum concentrations were generally
attained at 0.5 h post dose (i.e. at the end of infusion). In
accordance with the literature34, concentrations declined
rapidly; at 2 h after start of infusion they were below the
lower limit of quantification (LLQ) in about one third of
the subjects and at 3 h after start of infusion nearly all con-
centrations were below LLQ. To compare maximum con-
centrations between treatment groups median instead of
mean concentration values were used due to the compar-
atively high variability of single values. Medians of con-
centrations were comparable across the treatment groups.
For the Cilengitide and gemcitabine group median con-
centrations were 6960 ng/mL (n = 12) and 7490 ng/mL (n
= 11) in Weeks 1 and 2, respectively. For gemcitabine
alone, median concentrations of 10600 ng/mL (n = 5)
and 6060 ng/mL (n = 5) were observed for Weeks 1 and 2,
respectively. Mean and median concentrations measured
at 1 h and 2 h after start of infusion were of the same mag-
nitude across all treatment groups.
Discussion
This was a phase II, randomized, open-label study of gem-
citabine with or without the cyclic pentapeptide Cilen-
gitide conducted in chemotherapy-naive patients with
unresectable pancreatic cancer. The patient demographic
parameters, past medical history, and concomitant medi-
cations, were balanced across the treatment groups. The
TNM classifications for the study population were compa-
rable between treatment groups. All the patients had a
clinical tumor stage at the start of the study of at least stage
III (clinically unresectable), with the majority of patients
being classified as stage IV.
Efficacy
The median overall survival times of 7.7 months for
patients receiving gemcitabine alone and 6.7 months for
patients receiving Cilengitide and gemcitabine compare
with the results from phase III trials, which have reported
median survival times of 4.6 to 6.6 months [27-30] for
gemcitabine alone. Both the response rate (17% vs. 14%)
and the tumor growth control rates (54% vs. 56%) were
similar in the combination treatment group and the gem-
citabine alone group of patients. These overall response
rates are in the previously reported range of 6% to 26%
[31-34], which have been observed for single agent gem-
citabine in patients with pancreatic cancer. Although there
are currently few published studies for Cilengitide, in a
phase I study in advanced cancer prolonged stable disease
was seen in two patients with renal cell cancer and one
patient with colorectal cancer [35]. Other recent
approaches towards antiangiogenic or other targeted ther-
apies in combination with gemcitabine like the treatment
with the chimeric monoclonal EGFR-antibody cetuximab
[30] or the anti-VEGF-agent bevacizumab [31] seem to be
more promising regarding response rates (12,2 % and 21
% respectively) but not regarding median overall survival
Table 3: Response Rate Data
Cilengitide + Gemcitabine n = 46 Gemcitabine n = 43
No. patients % No. patients %
Complete response 0 0% 1 2%
Partial response 8 17% 5 12%
Stable disease 17 37% 18 42%
Progressive disease 12 26% 10 23%
Missing/not assessable 9 20% 9 21%
Response rate 8 17% 6 14%
Tumor growth control 25 54% 24 56%
Table 2: Survival Data
Cilengitide + Gemcitabine n = 46 Gemcitabine n = 43
Number of deaths 41 37
Median survival (95% CI), days 204 (154–292) 234 (137–290)
1-year survival (95% CI) 0.15 (0.04–0.26) 0.24 (0.11–0.37)
Median PFS (95% CI), days 110 (59–154) 115 (62–178)
Abbreviation: CI, confidence interval.BMC Cancer 2006, 6:285 http://www.biomedcentral.com/1471-2407/6/285
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times (7.1 and 8,8 months respectively). Phase III trials
with this agents are currently ongoing.
There were no apparent differences observed in the
present study between treatment groups in the changes in
serum marker levels over time. Despite the high variability
of the CA19-9 data, the intra-individual course of CA19-9
concentrations went in line with the clinical course, par-
ticularly in responders, consistent with reports in the liter-
ature [36,37]. No apparent relationships were observed
between the plasma or serum VEGF or bFGF, or urinary
bFGF concentrations and either treatment group, nor was
there any consistent pattern in the changes in the ang-
iogenic growth factor levels with time. The evaluation of
biological markers of angiogenesis was carried out to
investigate their potential as surrogate markers of anti-
tumor anti-angiogenic activity. The lack of change in the
levels of the markers with time, also seen in phase I stud-
ies of Cilengitide [38], can be interpreted two ways. Either
the finding is consistent with the lack of clinical benefit
for Cilengitide or it suggests that the markers studied are
not the best surrogate markers of the activity of an integrin
inhibitor. Other approaches are being investigated such as
dynamic contrast magnetic resonance imaging of tumor
perfusion, the level of endothelial cell apoptosis and
microvessel density as a measure for tumor angiogenesis,
but the lack of clinical data for integrin antagonists [39-
41] leaves no room for conclusions.
With regard to the QoL scores, from week 9 onwards the
dropout rate was considerable, resulting in a potential
overestimation of the functioning scales and underesti-
mation of the symptom scores. However, a higher
number of patients reported an improved QoL score in
the Cilengitide and gemcitabine group compared with the
gemcitabine alone treatment group. Although again draw-
ing firm conclusions is difficult, the data do show that the
combined treatment had no adverse effects on patient
QoL compared with gemcitabine alone.
Safety
The number of cycles received and the mean duration of
treatment were broadly similar for the two treatment
groups, and the RDIs were very close to the planned dose
intensity. The profile of adverse events was consistent with
the underlying disease and was similar across the treat-
ment groups, with the exception of leukopenia (most fre-
quent in the Cilengitide and gemcitabine group).
Although the total number of adverse events was higher in
the drug combination group, the patients in the Cilen-
gitide and gemcitabine group were seen more frequently
by the investigators than patients in the gemcitabine
alone group, and together with the open-label nature of
Table 5: Overview of Adverse Events
Event Grade Cilengitide + Gemcitabine n = 44 Gemcitabine n = 42
No. Pts (%) No. Pts (%)
AE All 923 100% 755 100%
Grade 1/2 812 27% 617 17%
Grade 3/4 111 73% 138 83%
SAE All 50 55% 64 71%
Adverse events with onset during the treatment phase.
Abbreviations: Pts, patients; AE, adverse event; SAE, serious adverse event.
Table 4: Drug Exposure
Cilengitide + Gemcitabine n = 44 Gemcitabine n = 42
Cilengitide Gemcitabine Gemcitabine
Mean duration ± SD, days 134 ± 89 120 ± 75
Median duration (range), days 133 (1–344) 135 (1–330)
Mean no. cycles ± SD 4.8 ± 4.0 4.1 ± 2.7
Median no. cycles (range) 4.5 (0–19) 4.5 (1–12)
Mean RDI ± SD 1st 6 mths (range), % 93 ± 11 94 ± 11 89 ± 15
Median RDI 1st 6 mths (range), % 97 (53–101) 99 (55–104) 96 (47–105)
Abbreviations: SD, standard deviation; RDI, relative dose intensity; mths, months.
RDI = % of planned total dosageBMC Cancer 2006, 6:285 http://www.biomedcentral.com/1471-2407/6/285
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this study may have contributed to differences between
the two treatment groups. Serious adverse events were
reported more frequently by patients in the gemcitabine
alone group (71%) than in the Cilengitide and gemcitab-
ine group (55%), and might indicate that the combina-
tion treatment was reducing some of the symptoms of the
disease. The lack of any Cilengitide exacerbation of gem-
citabine toxicity is consistent with the findings from the
published phase 1 study of single agent Cilengitide where
no dose limiting toxicity was recorded and it was not pos-
sible to define a maximum tolerated dose [42].
Changes in biochemical, hematological, and urinalysis
parameters during the study did not indicate any patterns
for clinical concern and mainly reflected the progression
of the underlying disease. There was no excess of increased
elevations of alkaline phosphatase or bilirubin levels in
the patients who received Cilengitide and gemcitabine in
comparison with gemcitabine alone. No treatment-associ-
ated death were observed on study.
Vital signs, physical examinations, weights, chest X-rays,
and electrocardiograms also did not show any matters of
Table 7: Serious adverse events possibly related to study treatment
Treatment group Adverse event Grade Number of events
Cilengitide and gemcitabine Myocardial infarction 4 1
Apoplexia 4 1
Thrombocytopenia 3 1
Exanthema 1 1
Weakness 3 2
Nausea 3 1
Anaphylactic reaction 4 1
Pulmonary embolism 4 1
Gastrointestinal hemorrhage 3 1
Hypotension1 31
Erysipelas1 31
Gemcitabine Anorexia 3 1
Exanthema 2 1
Depression 3 1
Dyspnea 3 2
Epistaxis 2 1
Pneumonia 2 1
Condition reduced1 31
1Relationship "not assessable" by investigator; therefore, considered to be possibly related.
Table 6: Adverse events occurring in at least 5% of patients considered to be possibly related to treatment
Adverse events (% of patients)
Cilengitide + Gemcitabine n = 44 Gemcitabine n = 42
Nausea 36% 38%
Leukopenia 36% 26%
Thrombocytopenia 34% 33%
Anemia 27% 26%
Fatigue 23% 19%
Vomiting 18% 26%
Fever 11% 10%
Shivering 14% 2%
Peripheral edema 9% 5%
Headache 9% 0%
Sweating increased 11% 2%
Asthenia 7% 10%
Edema 7% 5%
Dyspepsia 7% 7%
Anorexia 7% 14%
Hair changes 5% 12%BMC Cancer 2006, 6:285 http://www.biomedcentral.com/1471-2407/6/285
Page 10 of 12
(page number not for citation purposes)
clinical concern. Overall, the safety evaluations suggest
that Cilengitide did not adversely affect the safety and tol-
erability of gemcitabine in the group of patients studied.
Pharmacokinetics
The mean Cilengitide CL was 54.2 ml/min/m2, which is
low compared with hepatic and renal blood flow (and less
than glomerular filtration rate) in man. Volume of distri-
bution at steady state ranged between 8 and 16 L/m2,
nominally equivalent to the extracellular fluid volume.
The small volume of distribution and low plasma clear-
ance manifests as a relatively short apparent terminal half-
life of 3 hours. The short half-life of Cilengitide may have
contributed to the lack of clinical benefit seen in this
study. Continuous IV infusions or more frequent dosing
schedule are therefore worth exploring in future studies.
Pharmacokinetic parameters were similar to those from a
published study of Cilengitide alone in patients with
advanced solid tumors [43]. This finding indicates that
the pharmacokinetics of Cilengitide are unaffected by the
concomitant administration of gemcitabine. Gemcitabine
concentrations were also in good agreement with the lit-
erature values [44] and comparable across the treatment
groups suggesting the absence of a clinically relevant
impact of Cilengitide on gemcitabine pharmacokinetics.
Conclusion
The combination of Cilengitide and gemcitabine was well
tolerated with no observed differences in the treatment
groups on either adverse effects on the safety, tolerability
and pharmacokinetics.
Efficacy results compare with previously reported gemcit-
abine single agent studies in this setting and considering
that there was no inference planned, no difference was
observed between the treatment groups of this trial.
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